Royalty Pharma Dividends and Buybacks
Dividend criteria checks 2/6
Royalty Pharma is a dividend paying company with a current yield of 3.37% that is well covered by earnings.
Key information
3.4%
Dividend yield
1.4%
Buyback Yield
| Total Shareholder Yield | 4.8% |
| Future Dividend Yield | 3.7% |
| Dividend Growth | 20.6% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$0.840 |
| Payout ratio | 32% |
Recent dividend and buyback updates
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14
Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Recent updates
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt
Dec 05Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, RPRX has been paying a dividend for less than 10 years.
Growing Dividend: RPRX's dividend payments have increased, but the company has only paid a dividend for 4 years.
Dividend Yield vs Market
| Royalty Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RPRX) | 3.4% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (RPRX) (up to 3 years) | 3.7% |
Notable Dividend: RPRX's dividend (3.37%) is higher than the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: RPRX's dividend (3.37%) is low compared to the top 25% of dividend payers in the US market (4.51%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (32.5%), RPRX's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: RPRX is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Royalty Pharma plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Charlie Yang | BofA Global Research |
| Jason Matthew Gerberry | BofA Global Research |